CA Patent

CA3195702A1 — Process of reworking

Assigned to Boehringer Ingelheim International GmbH · Expires 2022-04-21 · 4y expired

What this patent protects

The invention describes a process for reworking of a crystallization product comprising drying and homogenization. The crystallization product is crystalline [5-(methylsulfonyl)-2- {[(2R)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]{(1R,5R)-1-[5-(trifluoromethyl)-1,2-oxazol-3-5 yl]-3-a…

USPTO Abstract

The invention describes a process for reworking of a crystallization product comprising drying and homogenization. The crystallization product is crystalline [5-(methylsulfonyl)-2- {[(2R)-1,1,1-trifluoropropan-2-yl]oxy}phenyl]{(1R,5R)-1-[5-(trifluoromethyl)-1,2-oxazol-3-5 yl]-3-azabicyclo[3.1.0]hex-3-yl}methanone. The product is dried in a tray dryer or in a pan dryer und subsequently homogenized.

Drugs covered by this patent

Patent Metadata

Patent number
CA3195702A1
Jurisdiction
CA
Classification
Expires
2022-04-21
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.